On April 14, 2023 Geneius Biotechnology, Inc., an immuno-oncology company developing a best-in-class personalized RNA-enabled T cell therapy platform that generates a robust immune response to solid and liquid cancers, reported that the company will present a poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida (Press release, Geneius Biotechnology, APR 14, 2023, View Source [SID1234630111]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract will be available on the AACR (Free AACR Whitepaper) meeting website. The poster will be available online at www.geneiusbiotech.com following the presentation.
Poster Presentation Details
Abstract 4067 – RNA primed SMAR-T cells against multiple driver mutations, all HLA’s, designed for first line therapy
Date/Time: Tuesday, April 18, 2023, 9:00 AM – 12:30 PM ET
Session: Adoptive Cell and Natural Killer Cell Therapy
Presenter: Alfred E. Slanetz, Ph. D.
Location: Orange County Convention Center, Poster Section 22, Poster Board 19
About RNA primed SMAR-T cells
SMAR-T is an RNA-enabled T cell therapy targeting multiple driver mutations to extend immunotherapy to the 95% of solid tumor patients who currently don’t have an effective anti-PD1 immunotherapy. Anti-PD1 (Keytruda and Opdivo) provides great benefit to patients whose cancers have high mutational burden by recruiting new T cells from the blood into the tumor and unleashing those previously dormant T cells. Geneius’s treatments deliver a high dose of these cells, whose T cell receptors (TCRs) are "educated" using our proprietary RNA technology to create multiple TCRs recognizing multiple cancer driver mutations in the context of all HLA for the 95% of patients whose tumors have low of mutational burden. SMAR-T expands T cells reactive to multiple driver mutations from the blood with all of the T cell phenotypes for an ideal cancer therapy. The "ultimate TCR-T": SMAR-T uses the entire repertoire of T-cell receptors and HLA in a parallel system targeting multiple, specific cell-surface and internal driver mutations. However, unlike current TCR-T, SMAR-T works with every patient’s HLA, recognizes multiple peptides, is cost effective to manufacture and has no cross-reactivity.
SMAR-T cells kill tumor cells but not normal cells, needing only one amino acid difference to distinguish a cancer mutation from normal. In a single closed system production run, we produce SMAR-T to target greater than 20 driver mutations efficiently and cost effectively in a disposable bioreactor. T cells targeting multiple mutations prevent the cancer from "escaping" therapy by a cell not expressing a particular mutation and allows the T cell product to combat heterogenous solid tumors. Our key product is SMAR-T targeting solid tumors starting with Melanoma, Lung and Pancreatic cancer. We collaborate with Yale (CT) and Mount Sinai (NY/NJ) to conduct clinical trials and phase I manufacturing with clinical data anticipated in 2024.